Thibault De La Motte Rouge
Thibault De La Motte Rouge is an expert in Oncology at Centre Eugène Marquis (France). As of October 2026, ScienceLeadR ranks Thibault De La Motte Rouge in the top 1% of experts worldwide for Ovarian Neoplasms, Adnexal Diseases and Gonadal Disorders. Thibault De La Motte Rouge has authored 179 publications, the most recent in 2025, and is an investigator in 43 clinical trials, 18 of them ongoing. SLR score: 1,202 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Gynecology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2005 - 2026
Number : 179
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Role of platinum-free interval (PFI) and maintenance therapies in recurrent ovarian cancer to explain survival. An analysis from the French real-world ESME Ovarian Database. PMID 40779880 — neoplasms, drug therapy, maintenance, ovarian neoplasms, therapeutics, chemotherapy | Gynecol Oncol | 2025 | 0 |
| Predictive value of BRCA1/RAD51C methylation in HGSOC - An ancillary study of the PAOLA-1/ENGOT-ov25 phase 3 trial. PMID 40513287 — research design, neoplasms, bevacizumab, predictive value of tests, maintenance, genes, brca1, mutation | Eur J Cancer | 2025 | 0 |
| Consensus on drivers of maintenance treatment choice and patterns of care in advanced ovarian cancer. PMID 39448084 — recombination, genetic, poly(adp-ribose) polymerase inhibitors, poly(adp-ribose) polymerases, homologous recombination, genital neoplasms, female, neoplasms, disease progression, bevacizumab, poly adenosine diphosphate ribose, maintenance, ovarian neoplasms, response evaluation criteria in solid tumors, therapeutics, mutation | Int J Gynecol Cancer | 2025 | 0 |
| Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER-positive/HER2-negative breast cancer. PMID 40623476 — circulating tumor dna, breast neoplasms, neoplasms, survival analysis, hormones, breast, therapeutics, dna, mutation | Ann Oncol Top journal | 2025 | 0 |
| PARP inhibitors as maintenance therapy in ovarian cancer after platinum-sensitive recurrence: real-world experience from the Unicancer network. PMID 40349134 — poly(adp-ribose) polymerase inhibitors, ovary, neoplasms, drug therapy, maintenance, ovarian neoplasms, therapeutics, chemotherapy | Oncologist | 2025 | 1 |
Clinical Studies 43
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
18 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A MULTICENTER SEEKING SIGNAL RANDOMISED OPEN LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS 2024-514032-25-00 — uterine cervical neoplasms, neoplasms, nivolumab | Phase 2 | Active not recruiting | 2024 |
| Beamion BCGC 1 A study to find a suitable dose of zongertinib used alone and in combination with other treatments to test whether it helps people with different types of HER2 cancer that has spread 2023-509566-38-00 — breast neoplasms, esophagogastric junction, neoplasms, adenocarcinoma, breast, therapeutics, colorectal neoplasms, capecitabine, trastuzumab | Phase 1/Phase 2 | Recruiting | 2024 |
| Ribociclib in combination with endocrine therapy in patients with estrogen receptor positive and HER2 negative breast cancer with high risk of recurrence 2023-508827-10-00 — estrogens, safety, breast neoplasms, receptors, estrogen, neoplasms, letrozole, breast, therapeutics | Phase 2 | Active not recruiting | 2025 |
| Early detection of triple negative breast cancer relapse (CUPCAKE) 2022-501562-22-01 — triple negative breast neoplasms, breast neoplasms, neoplasms, breast | Phase 2 | Recruiting | 2026 |
| A clinical study of sac TMT in people with breast cancer (MK 2870 032) 2024-520190-12-00 — triple negative breast neoplasms, safety, breast neoplasms, paclitaxel, neoplasms, drug therapy, respect, hormones, breast, neoadjuvant therapy, therapeutics, carboplatin, chemotherapy | Phase 3 | Recruiting | 2025 |
LeadR Networks
Main global connection map